Literature DB >> 18342019

Influence of PDZK1 on lipoprotein metabolism and atherosclerosis.

Olivier Kocher1, Ayce Yesilaltay, Ching-Hung Shen, Songwen Zhang, Kathleen Daniels, Rinku Pal, Jianzhu Chen, Monty Krieger.   

Abstract

PDZK1 is a scaffold protein containing four PDZ protein interaction domains, which bind to the carboxy termini of a number of membrane transporter proteins, including ion channels (e.g., CFTR) and cell surface receptors. One of these, the HDL receptor, scavenger receptor class B type I (SR-BI), exhibits a striking, tissue-specific dependence on PDZK1 for its expression and activity. In PDZK1 knockout (KO) mice there is a marked reduction of SR-BI protein expression (approximately 95%) in the liver, but not in steroidogenic tissues or, as we show in this report, in bone marrow- or spleen-derived macrophages, or lung-derived endothelial cells. Because of hepatic SR-BI deficiency, PDZK1 KO mice exhibit dyslipidemia characterized by elevated plasma cholesterol carried in abnormally large HDL particles. Here, we show that inactivation of the PDZK1 gene promotes the development of aortic root atherosclerosis in apolipoprotein E (apoE) KO mice fed with a high fat/high cholesterol diet. However, unlike complete SR-BI-deficiency in SR-BI/apoE double KO mice, PDZK1 deficiency in PDZK1/apoE double knockout mice did not result in development of occlusive coronary artery disease or myocardial infarction, presumably because of their residual expression of SR-BI. These findings demonstrate that deficiency of an adaptor protein essential for normal expression of a lipoprotein receptor promotes atherosclerosis in a murine model. They also define PDZK1 as a member of the family of proteins that is instrumental in preventing cardiovascular disease by maintaining normal lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342019      PMCID: PMC2421013          DOI: 10.1016/j.bbadis.2008.02.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  50 in total

1.  Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice.

Authors:  F E Thorngate; L L Rudel; R L Walzem; D L Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

2.  Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I.

Authors:  M Ikemoto; H Arai; D Feng; K Tanaka; J Aoki; N Dohmae; K Takio; H Adachi; M Tsujimoto; K Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Influence of the HDL receptor SR-BI on atherosclerosis.

Authors:  M Krieger; K Kozarsky
Journal:  Curr Opin Lipidol       Date:  1999-12       Impact factor: 4.776

Review 4.  Mouse models of atherosclerosis.

Authors:  C A Reardon; G S Getz
Journal:  Curr Opin Lipidol       Date:  2001-04       Impact factor: 4.776

5.  Down-regulation of intestinal scavenger receptor class B, type I (SR-BI) expression in rodents under conditions of deficient bile delivery to the intestine.

Authors:  P J Voshol; M Schwarz; A Rigotti; M Krieger; A K Groen; F Kuipers
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

6.  Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice.

Authors:  P Mardones; V Quiñones; L Amigo; M Moreno; J F Miquel; M Schwarz; H E Miettinen; B Trigatti; M Krieger; S VanPatten; D E Cohen; A Rigotti
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

7.  Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice.

Authors:  Anne Braun; Bernardo L Trigatti; Mark J Post; Kaori Sato; Michael Simons; Jay M Edelberg; Robert D Rosenberg; Mark Schrenzel; Monty Krieger
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

8.  Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor.

Authors:  X Gu; K Kozarsky; M Krieger
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

9.  SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance.

Authors:  Lei Cai; Ailing Ji; Frederick C de Beer; Lisa R Tannock; Deneys R van der Westhuyzen
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

10.  Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein.

Authors:  C K Garcia; K Wilund; M Arca; G Zuliani; R Fellin; M Maioli; S Calandra; S Bertolini; F Cossu; N Grishin; R Barnes; J C Cohen; H H Hobbs
Journal:  Science       Date:  2001-04-26       Impact factor: 47.728

View more
  23 in total

1.  Noncanonical role of the PDZ4 domain of the adaptor protein PDZK1 in the regulation of the hepatic high density lipoprotein receptor scavenger receptor class B, type I (SR-BI).

Authors:  Kosuke Tsukamoto; Thomas E Wales; Kathleen Daniels; Rinku Pal; Ren Sheng; Wonhwa Cho; Walter Stafford; John R Engen; Monty Krieger; Olivier Kocher
Journal:  J Biol Chem       Date:  2013-05-17       Impact factor: 5.157

Review 2.  Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions.

Authors:  Wen-Jun Shen; Jie Hu; Zhigang Hu; Fredric B Kraemer; Salman Azhar
Journal:  Metabolism       Date:  2014-03-21       Impact factor: 8.694

Review 3.  Genetic basis of atherosclerosis: insights from mice and humans.

Authors:  Ioannis M Stylianou; Robert C Bauer; Muredach P Reilly; Daniel J Rader
Journal:  Circ Res       Date:  2012-01-20       Impact factor: 17.367

4.  Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37.

Authors:  Hogyoung Kim; Zakaria Y Abd Elmageed; Christian Davis; Ali H El-Bahrawy; Amarjit S Naura; Ibrahim Ekaidi; Asim B Abdel-Mageed; A Hamid Boulares
Journal:  Mol Med       Date:  2014-07-14       Impact factor: 6.354

5.  In vitro and in vivo analysis of the binding of the C terminus of the HDL receptor scavenger receptor class B, type I (SR-BI), to the PDZ1 domain of its adaptor protein PDZK1.

Authors:  Olivier Kocher; Gabriel Birrane; Kosuke Tsukamoto; Sara Fenske; Ayce Yesilaltay; Rinku Pal; Kathleen Daniels; John A A Ladias; Monty Krieger
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

6.  Identification of the PDZ3 domain of the adaptor protein PDZK1 as a second, physiologically functional binding site for the C terminus of the high density lipoprotein receptor scavenger receptor class B type I.

Authors:  Olivier Kocher; Gabriel Birrane; Ayce Yesilaltay; Sharon Shechter; Rinku Pal; Kathleen Daniels; Monty Krieger
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

7.  Carboxy-terminal deletion of the HDL receptor reduces receptor levels in liver and steroidogenic tissues, induces hypercholesterolemia, and causes fatal heart disease.

Authors:  Rinku Pal; Qingen Ke; German A Pihan; Ayce Yesilaltay; Marsha L Penman; Li Wang; Chandramohan Chitraju; Peter M Kang; Monty Krieger; Olivier Kocher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-30       Impact factor: 4.733

Review 8.  Platelet hyperreactivity, scavenger receptors and atherothrombosis.

Authors:  M Valiyaveettil; E A Podrez
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 9.  Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI.

Authors:  Olivier Kocher; Monty Krieger
Journal:  Curr Opin Lipidol       Date:  2009-06       Impact factor: 4.776

10.  Loss of PDZK1 causes coronary artery occlusion and myocardial infarction in Paigen diet-fed apolipoprotein E deficient mice.

Authors:  Ayce Yesilaltay; Kathleen Daniels; Rinku Pal; Monty Krieger; Olivier Kocher
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.